Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders

References

• Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition. Lyon: IARC; 2017.
   Google Scholar
• Matutes E, Owusu-Ankomah K, Morilla R, et al. The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. Leukemia. 1994;8:1640–1645.
   PubMed Web of Science ®Google Scholar
• Moreau EJ, Matutes E, A'Hern RP, et al. Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b). Am J Clin Pathol. 1997;108(4):378–382.
   PubMed Web of Science ®Google Scholar
• Oscier D, Dearden C, Erem E, et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia. Br J Haematol. 2012;159(5):541–564.
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760.
   PubMed Web of Science ®Google Scholar
• D'Arena G, Vitale C, Rossi G, et al. CD200 included in a 4-marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. Hematol Oncol. 2018;36(3):543–546.
   Web of Science ®Google Scholar
• Hoffmann J, Rother M, Kaiser U, et al. Determination of CD43 and CD200 surface expression improves accuracy of B‐cell lymphoma immunophenotyping. Cytometry B Clin Cytom. 2020;98(6):476–482.
   PubMed Web of Science ®Google Scholar
• Köhnke T, Wittmann VK, Bücklein VL, et al. Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200. Br J Haematol. 2017;179(3):480–487.
   PubMed Web of Science ®Google Scholar
• Mora A, Bosch R, Cuellar C, et al. CD200 is a useful marker in the diagnosis of chronic lymphocytic leukemia. Cytometry. 2019;96(2):143–148.
   PubMedGoogle Scholar
• Sorigue M, Raya M, Vergara S, et al. Concordance between flow cytometry CLL scores. Int J Lab Hematol. 2021;43(4):743–751.
   PubMed Web of Science ®Google Scholar
• Jung G, Eisenmann JC, Thiébault S, et al. Cell surface CD43 determination improves diagnostic precision in late B-cell diseases. Br J Haematol. 2003;120(3):496–499.
   PubMed Web of Science ®Google Scholar
• Li Y, Tong X, Huang L, et al. A new score including CD43 and CD180: increased diagnostic value for atypical chronic lymphocytic leukemia. Cancer Med. 2021;10(13):4387–4396.
   PubMed Web of Science ®Google Scholar
• Zhu J, Raimbault A, Sourdeau E, et al. Holding on to the Matutes score while dropping FMC7: new opportunity from standardised approaches in multiparameter flow cytometry. Br J Haematol. 2020;190(4):e255–e258.
   PubMed Web of Science ®Google Scholar
• Güell N, Junca J, Raya M, et al. Overlap between CD23 and CD200 in leukemic lymphoproliferative disorders. Int J Lab Hematol. 2022;44(4):e149–e152.
   PubMedGoogle Scholar
• Sorigue M, Junca J, Ferra C, et al. FMOD expression in whole blood aids in distinguishing between chronic lymphocytic leukemia and other leukemic lymphoproliferative disorders. A pilot study. Cytometry B Clin Cytom. 2020;98(5):421–428.
   PubMed Web of Science ®Google Scholar
• Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33(9):1212–1216.
   PubMed Web of Science ®Google Scholar
• Jalal SD. The contribution of CD200 to the diagnostic accuracy of Matutes score in the diagnosis of chronic lymphocytic leukemia in limited resources laboratories. PLOS One. 2021;16(2):e0247491.
   PubMed Web of Science ®Google Scholar
• Shi Y, Liu L, Yang H, et al. The potential differential diagnosis value and clinical significance of CD35 expression in B-chronic lymphoproliferative disorders. Ann Transl Med. 2021;9(14):1166–1166.
   PubMed Web of Science ®Google Scholar
• Busch EL. Cut points and contexts. Cancer. 2021;127(23):4348–4355.
   PubMed Web of Science ®Google Scholar
• Hudson CA, Burack WR, Leary PC, et al. Clinical utility of classical and nonclassical monocyte percentage in the diagnosis of chronic myelomonocytic leukemia. Am J Clin Pathol. 2018;150(4):293–302.
   PubMed Web of Science ®Google Scholar
• Selimoglu-Buet D, Wagner-Ballon O, Saada V, et al. Characteristic repartition of monocyte subsets as a diagnostic signature of chronic myelomonocytic leukemia. Blood. 2015;125(23):3618–3626.
   PubMed Web of Science ®Google Scholar
• Calvo X, Garcia-Gisbert N, Parraga I, et al. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Adv. 2020;4(20):5285–5296.
   PubMed Web of Science ®Google Scholar
• Jung J, Concannon C, Shroff R, et al. Simple rules to guide expert classifications. J R Stat Soc A. 2020;183(3):771–800.
   Web of Science ®Google Scholar
• Pavlou M, Ambler G, Seaman S, et al. Review and evaluation of penalised regression methods for risk prediction in low‐dimensional data with few events. Stat Med. 2016;35(7):1159–1177.
   PubMed Web of Science ®Google Scholar
• Moraes LO, Pedreira CE, Barrena S, et al. A decision-tree approach for the differential diagnosis of chronic lymphoid leukemias and peripheral B-cell lymphomas. Comput Methods Programs Biomed. 2019;178:85–90.
   PubMed Web of Science ®Google Scholar
• Healey R, Naugler C, de Koning L, et al. A classification tree approach for improving the utilization of flow cytometry testing of blood specimens for B-cell non-Hodgkin lymphoproliferative disorders. Leuk Lymphoma. 2015;56(9):2619–2624.
   PubMed Web of Science ®Google Scholar
• Gaidano V, Tenace V, Santoro N, et al. A clinically applicable approach to the classification of B-cell non-Hodgkin lymphomas with flow cytometry and machine learning. Cancers. 2020;12(6):1684.
   PubMed Web of Science ®Google Scholar
• Loh W. Classification and regression trees. WIREs Data Mining Knowl Discov. 2011;1(1):14–23.
   Web of Science ®Google Scholar
• Miao Y, Cao L, Sun Q, et al. Spectrum and immunophenotyping of 653 patients with B-cell chronic lymphoproliferative disorders in China: a single-centre analysis. Hematol Oncol. 2018;36(1):121–127.
   PubMed Web of Science ®Google Scholar
• Morice WG, Kurtin PJ, Hodnefield JM, et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: comparative analysis of flow cytometry and tissue biopsy in 252 patients. Mayo Clin Proc. 2008;83(7):776–785.
   PubMed Web of Science ®Google Scholar
• Rawstron A, de Tute RM, Shingles J, et al. Improving the differential diagnosis of CD5+ B-lymphoproliferative disorders. EHA Meet; 2016. p. 586.
   Google Scholar
• Lesesve J-FF, Tardy S, Frotscher B, et al. Combination of CD160 and CD200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B-cell neoplasms. Int J Lab Hematol. 2015;37(4):486–494.
   PubMed Web of Science ®Google Scholar
• Fan L, Miao Y, Wu Y-J, et al. Expression patterns of CD200 and CD148 in leukemic B-cell chronic lymphoproliferative disorders and their potential value in differential diagnosis. Leuk Lymphoma. 2015;56(12):3329–3335.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kreuzer K-AA, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. Cytometry B Clin Cytom. 2018;94(1):121–128.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Juncà J, Sarrate E, et al. Expression of CD43 in chronic lymphoproliferative leukemias. Cytometry B Clin Cytom. 2018;94(1):136–142.
   PubMed Web of Science ®Google Scholar
• Falay M, Öztürk BA, Güneş K, et al. The role of CD200 and CD43 expression in differential diagnosis between chronic lymphocytic leukemia and mantle cell lymphoma. Turk J Haematol. 2018;35(2):94–98.
   PubMed Web of Science ®Google Scholar
• Pedersen CB, Olsen LR. Algorithmic clustering of single-cell cytometry data—how unsupervised are these analyses really? Cytometry A. 2020;97(3):219–221.
   PubMed Web of Science ®Google Scholar
• Duetz C, Bachas C, Westers TM, et al. Computational analysis of flow cytometry data in hematological malignancies: future clinical practice? Curr Opin Oncol. 2020;32(2):162–169.
   PubMed Web of Science ®Google Scholar
• Van Gassen S, Callebaut B, Van Helden MJ, et al. FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data. Cytometry A. 2015;87(7):636–645.
   PubMedGoogle Scholar
• Maecker HT, Rinfret A, D'Souza P, et al. Standardization of cytokine flow cytometry assays. BMC Immunol. 2005;6(1):13.
   PubMed Web of Science ®Google Scholar
• Mair F, Hartmann FJ, Mrdjen D, et al. The end of gating? An introduction to automated analysis of high dimensional cytometry data. Eur J Immunol. 2016;46(1):34–43.
   PubMed Web of Science ®Google Scholar
• Brooimans RA, van der Velden VHJ, Boeckx N, et al. Immunophenotypic measurable residual disease (MRD) in acute myeloid leukemia: is multicentric MRD assessment feasible? Leuk Res. 2019;76:39–47.
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Brandau S, Britten CM, et al. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study. Cancer Immunol Immunother. 2016;65(2):161–169.
   PubMed Web of Science ®Google Scholar
• Johansson U, McIver‐Brown N, Cullen M, et al. The flow cytometry myeloid progenitor count: a reproducible parameter for diagnosis and prognosis of myelodysplastic syndromes. Cytometry B Clin Cytom. 2021.
   Web of Science ®Google Scholar
• Payne D, Johansson U, Bloxham D, et al. Inter-laboratory validation of a harmonized PNH flow cytometry assay. Cytometry. 2018;94(5):736–743.
   Google Scholar
• D'Arena G, Vitale C, Coscia M, et al. External validation of the accuracy of ‘CLLflow score’. J Investig Med. 2018;66(7):e6.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Franch-Sarto M, Sarrate E, et al. Usefulness of the CLLflow score. Cytometry. 2018;94(6):950–952.
   PubMedGoogle Scholar
• Gautam A, Sreedharanunni S, Sachdeva MUS, et al. The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow – results from a single cent. Int J Lab Hematol. 2021;43(5):1123–1131.
   PubMed Web of Science ®Google Scholar
• Starostka D, Kriegova E, Kudelka M, et al. Quantitative assessment of informative immunophenotypic markers increases the diagnostic value of immunophenotyping in mature CD5-positive B-cell neoplasms. Cytometry B Clin Cytom. 2018;94(4):576–587.
   PubMed Web of Science ®Google Scholar
• Challagundla P, Jorgensen JL, Kanagal-Shamanna R, et al. Utility of quantitative flow cytometry immunophenotypic analysis of CD5 expression in small B-cell neoplasms. Arch Pathol Lab Med. 2014;138(7):903–909.
   PubMed Web of Science ®Google Scholar
• Bossuyt X, Fierz W, Meroni PL. Correspondence on “European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance” by Aringer et al. Ann Rheum Dis. 2021.
   Web of Science ®Google Scholar
• Fierz W, Bossuyt X. Likelihood ratio approach and clinical interpretation of laboratory tests. Front Immunol. 2021;12:655262.
   PubMed Web of Science ®Google Scholar
• Brush JE, Kaul S, Krumholz HM. Troponin testing for clinicians. J Am Coll Cardiol. 2016;68(21):2365–2375.
   PubMed Web of Science ®Google Scholar
• Oyaert M, Vermeersch P, De Hertogh G, et al. Combining antibody tests and taking into account antibody levels improves serologic diagnosis of celiac disease. Clin Chem Lab Med. 2015;53:1537–1546.
   PubMed Web of Science ®Google Scholar
• Fierz W, Bossuyt X. Likelihood ratios as value proposition for diagnostic laboratory tests. J Appl Lab Med. 2020;5(5):1061–1069.
   PubMedGoogle Scholar
• Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv62–iv71.
   PubMedGoogle Scholar
• Myles N, Giri P, Chim I, et al. The utility of CD200 expression and modified Matutes score in the diagnostic differentiation of mantle cell lymphoma and chronic lymphocytic leukemia using flow cytometry. Leuk Lymphoma. 2021;62(2):504–506.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Magnano L, Miljkovic MD, et al. Positive predictive value of CD200 positivity in the differential diagnosis of chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2020;98(5):441–448.
   PubMed Web of Science ®Google Scholar
• Sandes AF, de Lourdes Chauffaille M, Oliveira CRMC, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2013;86:98–105.
   PubMed Web of Science ®Google Scholar
• Ting YS, Smith SABC, Brown DA, et al. CD200 is a useful diagnostic marker for identifying atypical chronic lymphocytic leukemia by flow cytometry. Int J Lab Hematol. 2018;40(5):533–539.
   PubMed Web of Science ®Google Scholar
• Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332(7549):1080.
   PubMed Web of Science ®Google Scholar
• Gutiérrez G, Merino A, Domingo A, et al. EQAS for peripheral blood morphology in Spain: a 6-year experience. Int J Lab Hematol. 2008;30(6):460–466.
   PubMed Web of Science ®Google Scholar
• Alférez S, Merino A, Mujica LE, et al. Automatic classification of atypical lymphoid B cells using digital blood image processing. Int J Lab Hematol. 2014;36(4):472–480.
   PubMed Web of Science ®Google Scholar
• Soliman DS, Al‐Kuwari E, Al‐Abdulla R, et al. Biologic characterization of atypical chronic lymphocytic leukaemia. Int J Lab Hematol. 2021;44:e49–e51.
   PubMed Web of Science ®Google Scholar
• Hjalmar V, Kimby E, Matutes E, et al. Trisomy 12 and lymphoplasmacytoid lymphocytes in chronic leukemic B-cell disorders. Haematologica. 1998;83:602–609.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Raya M, Vergara S, et al. Refining the limits of borderline lymphoproliferative disorders. Cytometry B Clin Cytom. 2019;96(5):351–358.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac F, Lambert J, Chapiro E, et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenstrom’s macroglobulinemia. Haematologica. 2013;98(4):649–654.
   PubMed Web of Science ®Google Scholar
• Jang M-A, Yoo E-H, Kim K, et al. Chronic lymphocytic leukemia in Korean patients: frequent atypical immunophenotype and relatively aggressive clinical behavior. Int J Hematol. 2013;97(3):403–408.
   PubMed Web of Science ®Google Scholar
• Yan Y, Lv R, Xiong W, et al. Subtype distribution, clinical features, and survival in B-cell chronic lymphoproliferative disorders in China: a review of 1592 cases. Clin Lymphoma Myeloma Leuk. 2020;20(6):e270–e283.
   PubMed Web of Science ®Google Scholar
• Demir C, Kara E, Ekinci Ö, et al. Clinical and laboratory features of CD5-negative chronic lymphocytic leukemia. Med Sci Monit. 2017;23:2137–2142.
   PubMed Web of Science ®Google Scholar
• Romano C, Sellitto A, Chiurazzi F, et al. Clinical and phenotypic features of CD5-negative B cell chronic lymphoproliferative disease resembling chronic lymphocytic leukemia. Int J Hematol. 2015;101(1):67–74.
   PubMed Web of Science ®Google Scholar
• Navarro A, Clot G, Martínez-Trillos A, et al. Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica. 2017;102(9):e360–e363.
   PubMed Web of Science ®Google Scholar
• McCarthy BA, Yancopoulos S, Tipping M, et al. A seven-gene expression panel distinguishing clonal expansions of pre-leukemic and chronic lymphocytic leukemia B cells from normal B lymphocytes. Immunol Res. 2015;63(1–3):90–100.
   PubMed Web of Science ®Google Scholar
• Qin S-C, Xia Y, Miao Y, et al. MYD88 mutations predict unfavorable prognosis in chronic lymphocytic leukemia patients with mutated IGHV gene. Blood Cancer J. 2017;7(12):651.
   PubMedGoogle Scholar
• Jeromin S, Weissmann S, Haferlach C, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108–117.
   PubMed Web of Science ®Google Scholar
• Martínez-Trillos A, Pinyol M, Navarro A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123(24):3790–3796.
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–2506.
   PubMed Web of Science ®Google Scholar
• Shuai W, Lin P, Strati P, et al. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020;10(8):86.
   PubMed Web of Science ®Google Scholar
• Yi S, Yan Y, Jin M, et al. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia. 2021;35(8):2412–2415.
   PubMed Web of Science ®Google Scholar
• Baer C, Dicker F, Kern W, et al. Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia. Leukemia. 2017;31(6):1355–1362.
   PubMed Web of Science ®Google Scholar
• Shekhar R, Naseem S, Binota J, et al. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. Hematol Oncol Stem Cell Ther. 2021;14(3):231–239.
   PubMedGoogle Scholar
• Falay M, Serdar MA, Dalgali H, et al. Which markers should the used for diagnostic chronic lymphocytic leukemia immunophenotyping scoring system by flow cytometry? Clin Lab. 2019;65:2049–2055.
   Web of Science ®Google Scholar
• Goshaw JM, Gao Q, Wardrope J, et al. 14‐Color single tube for flow cytometric characterization of CD5+ B‐LPDs and high sensitivity automated minimal residual disease quantitation of CLL/SLL. Cytometry B Clin Cytom. 2021;100(4):509–518.
   PubMed Web of Science ®Google Scholar
• Sorigue M. CD43 in the malignant flow cytometry laboratory in 2020. Expert Rev Hematol. 2021;14(1):123–136.
   PubMed Web of Science ®Google Scholar
• Jevremovic D, Dronca RS, Morice WG, et al. CD5+ B-cell lymphoproliferative disorders: beyond chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Res. 2010;34(9):1235–1238.
   PubMed Web of Science ®Google Scholar
• Dronca RS, Jevremovic D, Hanson CA, et al. CD5-positive chronic B-cell lymphoproliferative disorders: diagnosis and prognosis of a heterogeneous disease entity. Cytometry. 2010;78B(S1):S35–S41.
   Google Scholar
• Horna P, Pearce KE, Ketterling RP, et al. Recurrent chromosomal abnormalities in tissues involved by chronic lymphocytic leukemia/small lymphocytic lymphoma. Am J Clin Pathol. 2021;157(2):286–292.
   Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.
   PubMed Web of Science ®Google Scholar
• Sorigue M, Junca J. Atypical chronic lymphocytic leukemia: brief historical overview and current usage of an equivocal concept. Int J Lab Hematol. 2019;41(1):e17–e19.
   PubMed Web of Science ®Google Scholar
• Soliman DS, Al‐Kuwari E, Siveen KS, et al. Downregulation of lymphoid enhancer‐binding factor 1 (LEF‐1) expression (by immunohistochemistry and/flow cytometry) in chronic lymphocytic leukemia with atypical immunophenotypic and cytologic features. Int J Lab Hem. 2021;43(3):515–525.
   PubMed Web of Science ®Google Scholar
• Zalcberg I, D'Andrea MG, Monteiro L, et al. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL – ERIC Recommendations. Hematol Transfus Cell Ther. 2020;42(3):269–274.
   PubMedGoogle Scholar
• Bazinet A, Rys RN, Barry A, et al. A 10-color flow cytometry panel for diagnosis and minimal residual disease in chronic lymphocytic leukemia. Leuk Lymphoma. 2021;62(10):2352–2359.
   PubMed Web of Science ®Google Scholar
• Kahneman D, Sibony O, Sunstein CR. Noise: a flaw in human judgment. New York: HarperCollins; 2021.
   Google Scholar
• Grove WM, Zald DH, Lebow BS, et al. Clinical versus mechanical prediction: a meta-analysis. Psychol Assess. 2000;12(1):19–30.
   PubMed Web of Science ®Google Scholar
• Collignon O. Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs. Clin Epidemiol. 2014;6:221–226.
   PubMed Web of Science ®Google Scholar
• Jain RK, Mehta R, Dimitrov R, et al. Atypical ductal hyperplasia: interobserver and intraobserver variability. Mod Pathol. 2011;24(7):917–923.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Ringold S, Khanna D, et al. Distinctions between diagnostic and classification criteria? Arthritis Care Res. 2015;67(7):891–897.
   Web of Science ®Google Scholar
• Elmore JG, Barnhill RL, Elder DE, et al. Pathologists’ diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study. BMJ. 2017;357:j2813.
   PubMedGoogle Scholar
• Egan C, Pittaluga S. Into the gray-zone: update on the diagnosis and classification of a rare lymphoma. Expert Rev Hematol. 2020;13(1):1–3.
   PubMed Web of Science ®Google Scholar
• Pilichowska M, Kritharis A, Evens AM. Gray zone lymphoma: current diagnosis and treatment options. Hematol Oncol Clin North Am. 2016;30(6):1251–1260.
   PubMed Web of Science ®Google Scholar
• Kempf W. A new era for cutaneous CD30-positive T-cell lymphoproliferative disorders. Semin Diagn Pathol. 2017;34(1):22–35.
   PubMed Web of Science ®Google Scholar
• van Dongen JJM, Lhermitte L, Böttcher S, et al. EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9):1908–1975.
   PubMed Web of Science ®Google Scholar
• Costa ES, Pedreira CE, Barrena S, et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia. 2010;24(11):1927–1933.
   PubMed Web of Science ®Google Scholar
• Böttcher S, Engelmann R, Grigore G, et al. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study. Blood Adv. 2021;6(3):976–992.
   Web of Science ®Google Scholar